Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript

Amir London: Building on what I just answered Annabel on the previous question, we believe that inhaled alpha-1 has significant advantages. We believe that in order to compete well in the market, especially with a powerhouse like Sanofi, it will be a good move for Kamada to partner the program with a strategic partner that has significant market and commercial capabilities and resources. And we’re looking for such type of partnership that will allow us to bring the product to the market in the fastest way and to compete well with the superior product.

Brian Ritchie: Maybe an update on the BD, product acquisition and opportunities and what might be available?

Amir London: We are proactively looking for products in the plasma space, as well as in transplantation. This is a specialty we’re covering to be very highly synergistic with our expertise and staff. Our BD team is working proactively, evaluating some opportunities. Once we have the news to update the market, we’ll be happy to do so.

Brian Ritchie: That’s all the questions that have come in over the web. I ask you to maybe make some closing comments.

Amir London: Yes. So in closing, we’re very pleased with our exceptional performance during 2023, and excited about the potential opportunities that lie ahead based on the amended KEDRAB agreement, existing ongoing late stage inhaled alpha-1 clinical program, and the strength of our commercial portfolio and balance sheet. We look forward to continuing to support clinicians and patients with important life-saving products that we develop, manufacture, and commercialize. We thank you all for your support, and remain committed in creating long-term shareholder value. We hope you stay safe and healthy. Thank you very much.

Operator: Thank You. This will conclude today’s conference. We disconnect your lines at this time. Thank you for your participation.